Summary

The PCR technologies market is projected to reach USD 21,430 million by 2031, up from USD 15,550 million in 2026, at a CAGR of 6.6% during 2026–2031.

The PCR technologies market is evolving toward higher efficiency, accuracy, sensitivity, and versatility, driven by advances in sophisticated instrumentation and high-fidelity enzymes. Real-time PCR (qPCR) enables real-time monitoring and quantitative analysis, while RT-PCR supports RNA analysis, gene expression studies, and viral detection. Digital PCR (dPCR) is gaining importance for applications requiring highly precise and sensitive absolute quantification, further broadening PCR's applications across research and diagnostics.

qPCR to account for largest market share in 2025.
qPCR is expected to hold the largest share of the PCR technologies market due to its established use in diagnostics and research, where precise quantification is required. By combining PCR amplification with real-time monitoring using fluorescent dyes or probes, qPCR enables quantitative analysis of target DNA at each cycle. Its broad utility and established role in molecular diagnostics and research support its widespread adoption.

Diagnostic laboratories to hold largest share in the market.
Diagnostic laboratories are expected to remain the largest end users of PCR technologies, driven by the growing need for rapid, sensitive, and accurate molecular testing. PCR is widely used for infectious disease detection, genetic testing, oncology, and disease monitoring. Rising testing volumes and demand for high-throughput workflows further support adoption. The shift toward automated, standardized, and integrated molecular testing systems is also strengthening PCR utilization in diagnostic laboratories.

North America is expected to retain the largest share of the PCR technologies market in 2026, supported by advanced healthcare infrastructure, strong adoption of molecular diagnostics, and substantial investments in genomics, precision medicine, and life-science research. The region also benefits from major PCR technology providers and the widespread use of PCR in clinical diagnostics, infectious disease testing, oncology, and genetic testing. Strong research capabilities and ongoing development of advanced PCR platforms further reinforce North America's market leadership.

A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
- By Designation: C-level-- 10%, Director-level–14%, and Others–76%
- By Region: North America–40%, Europe-30%, Asia Pacific–22%, Rest of the World - 8%.

Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Sansure Biotech Inc. (China), Becton, Dickinson and Company (US), Analytik Jena AG (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Illumina, Inc. (US), Bioneer Corporation (South Korea), PerkinElmer Inc. (US), and Hologic Inc. (US).

Research Coverage
The research report examines the market by product, material end-users, and geography. This research covers factors that are driving market expansion, analyzes current industry prospects and challenges, and provides specifics on the competitive landscape, including market leaders and small and medium enterprises. This research also estimates the revenue of different market segments by considering five regions and micro-market analysis.

Reasons to Buy the Report
The report will provide market leaders and new entrants with valuable information on revenue estimates for the overall market and its subsegments. It will help stakeholders understand the competitive landscape, enabling them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities.

This report provides insightful data on the following pointers:
- Market Penetration: In-depth coverage of product portfolios offered by the top players in the PCR technologies market
- Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the PCR technologies market
- Market Development: Insightful data on profitable developing areas
- Market Diversification: Details about recent developments and advancements in the PCR technologies market
- Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors

ページTOPに戻る

Table of Contents

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 STUDY SCOPE 29
1.3.1 SEGMENTS CONSIDERED 29
1.3.2 INCLUSIONS & EXCLUSIONS 30
1.3.3 YEARS CONSIDERED 30
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 31
1.5 SUMMARY OF CHANGES 31

2 EXECUTIVE SUMMARY 32
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 32
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 33
2.3 DISRUPTIVE TRENDS IN PCR TECHNOLOGIES MARKET 34
2.4 HIGH-GROWTH SEGMENTS 35

3 PREMIUM INSIGHTS 37
3.1 PCR TECHNOLOGIES MARKET OVERVIEW 37
3.2 PCR TECHNOLOGIES MARKET, BY REGION 38
3.3 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY AND PRODUCT 39
3.4 GEOGRAPHIC SNAPSHOT OF PCR TECHNOLOGIES MARKET 40

4 MARKET OVERVIEW 41
4.1 INTRODUCTION 41
4.2 MARKET DYNAMICS 41
4.2.1 DRIVERS 41
4.2.1.1 Laboratories Increasing outbreaks of infectious diseases/viral persistence 41
4.2.1.2 Development of miniaturized and portable point-of-care testing devices 42
4.2.1.3 High demand for technologically advanced molecular diagnostics 44
4.2.2 RESTRAINTS 45
4.2.2.1 Premium product pricing 45
4.2.2.2 Dearth of skilled healthcare professionals 46
4.2.3 OPPORTUNITIES 46
4.2.3.1 Increased investments in laboratory infrastructure 46
4.2.3.2 Rising number of applications in rare sequence detection 47
4.2.4 CHALLENGES 48
4.2.4.1 Technical limitations 48
4.2.4.2 Increased pricing pressure on market players 48
4.3 UNMET NEEDS AND WHITE SPACES 49
4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 50

5 INDUSTRY TRENDS 51
5.1 PORTER’S FIVE FORCES ANALYSIS 51
5.1.1 THREAT OF NEW ENTRANTS 52
5.1.2 THREAT OF SUBSTITUTES 52
5.1.3 BARGAINING POWER OF SUPPLIERS 52
5.1.4 BARGAINING POWER OF BUYERS 52
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 52
5.2 MACROECONOMIC OUTLOOK 52
5.2.1 INTRODUCTION 52
5.2.2 MACROECONOMIC INDICATORS 52
5.2.3 GDP TRENDS AND FORECAST 53
5.2.4 TRENDS IN GLOBAL PCR TECHNOLOGIES MARKET 53
5.3 VALUE CHAIN ANALYSIS 53
5.3.1 RESEARCH & DEVELOPMENT 54
5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 54
5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 54
5.4 ECOSYSTEM ANALYSIS 55
5.5 PRICING ANALYSIS 56
5.5.1 INDICATIVE PRICING REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER, 2025 56
5.5.2 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023–2025 57
5.5.2.1 North America 58
5.5.2.2 Europe 58
5.5.2.3 Asia Pacific 58
5.5.2.4 Rest of the World 58
5.6 TRADE DATA ANALYSIS 60
5.6.1 IMPORT DATA FOR HS CODE 3822 60
5.6.2 EXPORT DATA (HS CODE 3822) 61
5.7 KEY CONFERENCES & EVENTS, 2026–2027 62
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 62
5.9 INVESTMENT AND FUNDING SCENARIO 63
5.10 CASE STUDY ANALYSIS 64
5.10.1 MULTIPLEX DETECTION OF KRAS MUTATIONS IN CELL-FREE DNA USING DIGITAL PCR 64
5.10.2 PCR-BASED IDENTIFICATION OF ACINETOBACTER BAUMANNII SUPPORTS TARGETED INFECTION MANAGEMENT 64
5.11 IMPACT OF US TARIFFS – PCR TECHNOLOGIES MARKET 65
5.11.1 INTRODUCTION 65
5.11.2 KEY TARIFF RATES 65
5.11.3 PRICE IMPACT ANALYSIS 65
5.11.3.1 Impact on countries/regions 66
5.11.3.2 Impact on end-users 66

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACTS, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 67
6.1 KEY TECHNOLOGIES 67
6.1.1 THERMAL CYCLERS 67
6.1.2 REAL-TIME QUANTITATIVE PCR 67
6.1.3 PORTABLE AND POINT-OF-CARE PCR 67
6.2 COMPLEMENTARY TECHNOLOGIES 68
6.2.1 NEXT-GENERATION SEQUENCING 68
6.2.2 MICROARRAYS 68
6.2.3 LAB-ON-A-CHIP DEVICES 68
6.2.4 ROBOTICS AND AUTOMATION 68
6.3 PATENT ANALYSIS 68
6.4 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET 70
6.4.1 TOP USE CASES AND MARKET POTENTIAL 71
6.4.2 BEST PRACTICES FOLLOWED BY COMPANIES IN PCR TECHNOLOGIES MARKET 71
6.4.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION IN PCR TECHNOLOGIES MARKET 72
6.4.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS 72
6.4.5 CLIENT'S READINESS TO ADOPT AI/GEN AI IN PCR TECHNOLOGIES MARKET 73
6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 74

7 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 75
7.1 DECISION-MAKING PROCESS 75
7.2 KEY STAKEHOLDERS IN BUYING PROCESS AND EVALUATION CRITERIA 75
7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 76
7.2.2 KEY BUYING CRITERIA 76
7.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 77
7.4 UNMET NEEDS OF VARIOUS APPLICATIONS 78
7.5 REGULATORY LANDSCAPE 79
7.5.1 REGULATORY ANALYSIS 79
7.5.1.1 North America 79
7.5.1.1.1 US 79
7.5.1.1.2 Canada 79
7.5.1.2 Europe 80
7.5.1.3 Asia Pacific 80
7.5.1.3.1 Japan 80
7.5.1.3.2 China 81
7.5.1.3.3 India 82

8 PCR TECHNOLOGIES MARKET, BY PRODUCT 85
8.1 INTRODUCTION 86
8.2 REAGENTS AND CONSUMABLES 86
8.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET 86
8.3 INSTRUMENTS 87
8.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH 87
8.4 SOFTWARE AND SERVICES 88
8.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE IN ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH 88

9 PCR TECHNOLOGIES MARKET, BY TECHNIQUE 90
9.1 INTRODUCTION 91
9.2 REAL-TIME PCR 91
9.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH 91
9.3 CONVENTIONAL PCR 93
9.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH 93
9.4 DIGITAL PCR 94
9.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION 94
9.5 REVERSE TRANSCRIPTION PCR 95
9.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH 95
9.6 HOT-START PCR 96
9.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH 96
9.7 MULTIPLEX PCR 98
9.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH 98
9.8 OTHER PCR TECHNIQUES 99

10 PCR TECHNOLOGIES MARKET, BY APPLICATION 100
10.1 INTRODUCTION 101
10.2 DIAGNOSTIC APPLICATIONS 102
10.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH 102
10.3 GENOTYPING 103
10.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH 103
10.4 NUCLEIC ACID DETECTION 104
10.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH 104
10.5 GENE EXPRESSION ANALYSIS 105
10.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH 105
10.6 NUCLEIC ACID SYNTHESIS 106
10.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH 106
10.7 GENETIC SEQUENCING 107
10.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH 107
10.8 ENVIRONMENTAL APPLICATIONS 108
10.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR 108
10.9 STANDARD VALIDATION/VERIFICATION 109
10.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET 109
10.10 OTHER APPLICATIONS 110

11 PCR TECHNOLOGIES MARKET, BY END USER 111
11.1 INTRODUCTION 112
11.2 HOSPITAL LABORATORIES 112
11.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH 112
11.3 DIAGNOSTIC LABORATORIES 113
11.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH 113
11.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS 114
11.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET 114
11.5 PHARMA-BIOTECH COMPANIES 115
11.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES 115
11.6 OTHER END USERS 116

12 PCR TECHNOLOGIES MARKET, BY REGION 118
12.1 INTRODUCTION 119
12.2 NORTH AMERICA 119
12.2.1 US 123
12.2.1.1 US to dominate North American PCR technologies market during study period 123
12.2.2 CANADA 125
12.2.2.1 Supportive government initiatives for genomics research to aid market growth 125
12.3 EUROPE 126
12.3.1 GERMANY 129
12.3.1.1 Presence of well-established pharmaceutical and R&D industry to augment market growth 129
12.3.2 FRANCE 131
12.3.2.1 Increasing investments in life science R&D for infrastructural development to favor market growth 131
12.3.3 UK 132
12.3.3.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth 132
12.3.4 ITALY 133
12.3.4.1 Supportive government policies and high healthcare expenditure to boost market growth 133
12.3.5 SPAIN 135
12.3.5.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth 135
12.3.6 REST OF EUROPE 136
12.4 ASIA PACIFIC 137
12.4.1 CHINA 141
12.4.1.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth 141
12.4.2 JAPAN 143
12.4.2.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth 143
12.4.3 INDIA 144
12.4.3.1 Presence of large target patient population and high government healthcare expenditure to support market growth 144
12.4.4 AUSTRALIA 145
12.4.4.1 High healthcare expenditure to drive adoption of advanced PCR technologies 145
12.4.5 SOUTH KOREA 147
12.4.5.1 Improved medical tourism and prevalence of chronic diseases to propel market growth 147
12.4.6 REST OF ASIA PACIFIC 148
12.5 LATIN AMERICA 149
12.5.1 BRAZIL 152
12.5.1.1 Growing focus on proteomics and genomics research to drive market 152
12.5.2 MEXICO 153
12.5.2.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments 153
12.5.3 REST OF LATIN AMERICA 155
12.6 MIDDLE EAST & AFRICA 156
12.6.1 GCC COUNTRIES 159
12.6.1.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth 159
12.6.2 REST OF MIDDLE EAST & AFRICA 160

13 COMPETITIVE LANDSCAPE 162
13.1 INTRODUCTION 162
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 162
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET 162
13.3 REVENUE ANALYSIS, 2022–2025 164
13.4 MARKET SHARE ANALYSIS, 2025 164
13.4.1 PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2025 164
13.4.2 PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2025 165
13.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2025 165
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 168
13.5.1 STARS 168
13.5.2 EMERGING LEADERS 168
13.5.3 PERVASIVE PLAYERS 168
13.5.4 PARTICIPANTS 168
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 170
13.5.5.1 Company footprint 170
13.5.5.2 Product footprint 171
13.5.5.3 Application footprint 172
13.5.5.4 Technique footprint 173
13.5.5.5 End user footprint 174
13.5.5.6 Region footprint 175
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 176
13.6.1 PROGRESSIVE COMPANIES 176
13.6.2 RESPONSIVE COMPANIES 176
13.6.3 DYNAMIC COMPANIES 176
13.6.4 STARTING BLOCKS 176
13.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2025 178
13.6.5.1 Detailed list of key startups/SMEs players 178
13.6.5.2 Competitive benchmarking of key startups/SMEs 179
13.7 COMPANY VALUATION AND FINANCIAL METRICS, 2025 179
13.8 PRODUCT/BRAND COMPARISON 180
13.9 COMPETITIVE SCENARIO 181
13.9.1 PRODUCT LAUNCHES AND APPROVALS 181
13.9.2 DEALS 182
13.9.3 EXPANSIONS 183

14 COMPANY PROFILES 184
14.1 KEY PLAYERS 184
14.1.1 THERMO FISHER SCIENTIFIC INC. 184
14.1.1.1 Business overview 184
14.1.1.2 Products/Services/Solutions offered 185
14.1.1.3 Recent developments 187
14.1.1.3.1 Product launches and approvals 187
14.1.1.3.2 Deals 188
14.1.1.4 MnM view 188
14.1.1.4.1 Key strengths 188
14.1.1.4.2 Strategic choices 189
14.1.1.4.3 Weaknesses and competitive threats 189
14.1.2 F. HOFFMANN-LA ROCHE LTD. 190
14.1.2.1 Business overview 190
14.1.2.2 Products/Services/Solutions offered 191
14.1.2.3 Recent developments 192
14.1.2.3.1 Product launches and approvals 192
14.1.2.3.2 Deals 194
14.1.2.4 MnM view 194
14.1.2.4.1 Key strengths 194
14.1.2.4.2 Strategic choices 195
14.1.2.4.3 Weaknesses and competitive threats 195
14.1.3 AGILENT TECHNOLOGIES, INC. 196
14.1.3.1 Business overview 196
14.1.3.2 Products/Services/Solutions offered 197
14.1.3.3 Recent developments 199
14.1.3.3.1 Deals 199
14.1.3.3.2 Other developments 200
14.1.3.4 MnM view 200
14.1.3.4.1 Key strengths 200
14.1.3.4.2 Strategic choices 200
14.1.3.4.3 Weaknesses and competitive threats 200
14.1.4 BIO-RAD LABORATORIES, INC. 201
14.1.4.1 Business overview 201
14.1.4.2 Products/Services/Solutions offered 202
14.1.4.3 Recent developments 204
14.1.4.3.1 Product launches 204
14.1.4.3.2 Deals 205
14.1.4.4 MnM view 206
14.1.4.4.1 Key strengths 206
14.1.4.4.2 Strategic choices 206
14.1.4.4.3 Weaknesses and competitive threats 206
14.1.5 QIAGEN 207
14.1.5.1 Business overview 207
14.1.5.2 Products/Services/Solutions offered 208
14.1.5.3 Recent developments 210
14.1.5.3.1 Product launches and approvals 210
14.1.5.3.2 Deals 211
14.1.5.3.3 Expansions 212
14.1.5.4 MnM view 212
14.1.5.4.1 Key strengths 212
14.1.5.4.2 Strategic choices 213
14.1.5.4.3 Weaknesses and competitive threats 213
14.1.6 DANAHER CORPORATION 214
14.1.6.1 Business overview 214
14.1.6.2 Products/Services/Solutions offered 215
14.1.6.3 Recent developments 217
14.1.6.3.1 Product approvals 217
14.1.6.3.2 Deals 217
14.1.6.3.3 Expansions 218
14.1.7 BBOTT 219
14.1.7.1 Business overview 219
14.1.7.2 Products/Services/Solutions offered 220
14.1.7.3 Recent developments 221
14.1.7.3.1 Deals 221
14.1.8 TAKARA BIO INC. 222
14.1.8.1 Business overview 222
14.1.8.2 Products/Services/Solutions offered 223
14.1.8.3 Recent developments 224
14.1.8.3.1 Product launches 224
14.1.8.3.2 Deals 225
14.1.9 ANALYTIK JENA GMBH+CO. KG 226
14.1.9.1 Business overview 226
14.1.9.2 Products/Services/Solutions offered 226
14.1.9.3 Recent developments 227
14.1.9.3.1 Product launches 227
14.1.9.3.2 Deals 228
14.1.10 EPPENDORF SE 229
14.1.10.1 Business overview 229
14.1.10.2 Products/Services/Solutions offered 230
14.1.10.3 Recent developments 231
14.1.10.3.1 Product launches and approvals 231
14.1.10.3.2 Deals 231
14.1.11 MERCK KGAA 232
14.1.11.1 Business overview 232
14.1.11.2 Products/Services/Solutions offered 233
14.1.11.2.1 Deals 236
14.1.11.2.2 Expansions 236
14.1.12 BIONEER CORPORATION 237
14.1.12.1 Business overview 237
14.1.12.2 Products/Services/Solutions offered 238
14.1.12.3 Recent developments 239
14.1.12.3.1 Other developments 239
14.1.13 REVVITY 240
14.1.13.1 Business overview 240
14.1.13.2 Products/Services/Solutions offered 241
14.1.13.3 Recent developments 242
14.1.13.3.1 Product launches 242
14.1.13.3.2 Other developments 242
14.1.14 BECTON, DICKINSON AND COMPANY 243
14.1.14.1 Business overview 243
14.1.14.2 Products/Services/Solutions offered 244
14.1.14.3 Recent developments 245
14.1.14.3.1 Product launches and approvals 245
14.1.14.3.2 Deals 246
14.1.15 BIOMÉRIEUX 247
14.1.15.1 Business overview 247
14.1.15.2 Products/Services/Solutions offered 248
14.1.15.3 Recent developments 249
14.1.15.3.1 Product launches and approvals 249
14.1.16 STANDARD BIOTOOLS 250
14.1.16.1 Business overview 250
14.1.16.2 Products/Services/Solutions offered 251
14.1.17 HOLOGIC, INC. 253
14.1.17.1 Business overview 253
14.1.17.2 Products/Services/Solutions offered 254
14.1.17.3 Recent developments 255
14.1.17.3.1 Product launches 255
14.1.18 LONZA 256
14.1.18.1 Business overview 256
14.1.18.2 Products/Services/Solutions offered 257
14.1.19 ILLUMINA, INC. 258
14.1.19.1 Business overview 258
14.1.19.2 Products/Services/Solutions offered 259
14.1.20 SANSURE BIOTECH INC. 260
14.1.20.1 Business overview 260
14.1.20.2 Products/Services/Solutions offered 261
14.2 OTHER PLAYERS 262
14.2.1 PROMEGA CORPORATION 262
14.2.2 LIMING BIO 263
14.2.3 TRANSGEN BIOTECH CO., LTD. 264
14.2.4 DAAN GENE CO., LTD. 265
14.2.5 BIOBASE GROUP 266
14.2.6 NIPPON GENETICS EUROPE 267
14.2.7 STILLA 268
14.2.8 GENSCRIPT 269
14.2.9 NEW ENGLAND BIOLABS 270

15 RESEARCH METHODOLOGY 271
15.1 RESEARCH DATA 271
15.2 RESEARCH DESIGN 272
15.2.1 SECONDARY RESEARCH 272
15.2.1.1 Key secondary sources 272
15.2.1.2 Key objectives of secondary research 273
15.2.1.3 Key data from secondary sources 274
15.2.2 PRIMARY RESEARCH 274
15.2.2.1 Key primary sources 275
15.2.2.2 Key objectives of primary research 275
15.2.2.3 Key industry insights 276
15.2.2.4 Breakdown of primaries 276
15.3 MARKET SIZE ESTIMATION 277
15.3.1 BOTTOM-UP APPROACH 278
15.3.1.1 Company revenue estimation approach 279
15.3.1.2 Customer-based market estimation 279
15.3.1.3 Top-down approach 280
15.3.1.4 Primary interviews 281
15.3.2 GROWTH FORECAST 281
15.4 DATA TRIANGULATION 282
15.5 MARKET SHARE ASSESSMENT 283
15.6 STUDY ASSUMPTIONS 283
15.7 GROWTH ASSUMPTIONS 283
15.8 RISK ASSESSMENT 284
15.9 RESEARCH LIMITATIONS 284

16 APPENDIX 285
16.1 DISCUSSION GUIDE 285
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 289
16.3 CUSTOMIZATION OPTIONS 291
16.4 RELATED REPORTS 291
16.5 AUTHOR DETAILS 292

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 PCR TECHNOLOGIES MARKET: SEGMENTS CONSIDERED 29.
FIGURE 2 PCR TECHNOLOGIES MARKET: YEARS CONSIDERED 30.
FIGURE 3 MARKET SCENARIO 32.
FIGURE 4 GLOBAL PCR TECHNOLOGIES MARKET, 2024–2031 33.
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET, 2022–2026 33.
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PCR TECHNOLOGIES MARKET 34.
FIGURE 7 HIGH-GROWTH SEGMENTS IN PCR TECHNOLOGIES MARKET, 2025 35.
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PCR TECHNOLOGIES MARKET DURING FORECAST PERIOD 35.
FIGURE 9 NORTH AMERICA TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD 38.
FIGURE 10 REAGENTS AND CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN ASIA PACIFIC IN 2025 39.
FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2031 40.
FIGURE 12 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41.
FIGURE 13 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 51.
FIGURE 14 PCR TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS 54.
FIGURE 15 PCR TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS 55.
FIGURE 16 AVERAGE SELLING PRICE OF CONVENTIONAL PCR INSTRUMENTS,.
BY KEY PLAYER, 2025 57.
FIGURE 17 AVERAGE SELLING PRICE OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023–2025 59.
FIGURE 18 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND) 60.
FIGURE 19 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND) 61.
FIGURE 20 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS 62.
FIGURE 21 INVESTMENT AND FUNDING SCENARIO, 2019–2023 63.
FIGURE 22 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 63.
FIGURE 23 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION) 64.
FIGURE 24 PATENTS APPLIED AND GRANTED, 2016–2026 69.
FIGURE 25 PCR TECHNOLOGIES MARKET: IMPACT OF AI/GEN AI 70.
FIGURE 26 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 76.
FIGURE 27 KEY BUYING CRITERIA FOR TOP FOUR END USERS 77.
FIGURE 28 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT 120.
FIGURE 29 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT 138.
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN PCR TECHNOLOGIES MARKET,.
2022–2025 164.
FIGURE 31 PCR INSTRUMENTS MARKET SHARE ANALYSIS, 2025 165.
FIGURE 32 PCR REAGENTS AND CONSUMABLES MARKET SHARE ANALYSIS, 2025 165.
FIGURE 33 PCR SOFTWARE AND SERVICES MARKET SHARE ANALYSIS (2025) 166.
FIGURE 34 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 169.
FIGURE 35 PCR TECHNOLOGIES MARKET: COMPANY FOOTPRINT 170.
FIGURE 36 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX.
(STARTUPS/SMES), 2025 177.
FIGURE 37 EV/EBITDA OF KEY VENDORS, 2025 179.
FIGURE 38 YTD TOTAL RETURN AND 5-YEAR STOCK BETA VALUE FOR KEY PCR TECHNOLOGY VENDORS 180.
FIGURE 39 PCR TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 180.
FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 185.
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 191.
FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 197.
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 202.
FIGURE 44 QIAGEN: COMPANY SNAPSHOT 208.
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT 215.
FIGURE 46 ABBOTT: COMPANY SNAPSHOT 220.
FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT 223.
FIGURE 48 EPPENDORF SE: COMPANY SNAPSHOT 230.
FIGURE 49 MERCK KGAA: COMPANY SNAPSHOT 233.
FIGURE 50 BIONEER CORPORATION: COMPANY SNAPSHOT 237.
FIGURE 51 REVVITY: COMPANY SNAPSHOT 241.
FIGURE 52 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 244.
FIGURE 53 BIOMÉRIEUX: COMPANY SNAPSHOT 248.
FIGURE 54 STANDARD BIOTOOLS: COMPANY SNAPSHOT 251.
FIGURE 55 HOLOGIC, INC.: COMPANY SNAPSHOT 254.
FIGURE 56 LONZA: COMPANY SNAPSHOT 257.
FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT 259.
FIGURE 58 SANSURE BIOTECH INC.: COMPANY SNAPSHOT 260.
FIGURE 59 PCR TECHNOLOGIES MARKET: RESEARCH DATA 271.
FIGURE 60 PCR TECHNOLOGIES MARKET: RESEARCH DESIGN 272.
FIGURE 61 PCR TECHNOLOGIES MARKET: KEY DATA FROM SECONDARY SOURCES 274.
FIGURE 62 PCR TECHNOLOGIES MARKET: KEY PRIMARY SOURCES.
(DEMAND AND SUPPLY SIDES) 275.
FIGURE 63 PCR TECHNOLOGIES MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 276.
FIGURE 64 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 276.
FIGURE 65 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION 277.
FIGURE 66 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 278.
FIGURE 67 PCR TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION 279.
FIGURE 68 PCR TECHNOLOGIES MARKET: BOTTOM-UP APPROACH 280.
FIGURE 69 PCR TECHNOLOGIES MARKET: TOP-DOWN APPROACH 280.
FIGURE 70 DATA TRIANGULATION METHODOLOGY 282.
TABLE 1 PCR TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS 30.
TABLE 2 ADVANTAGES AND DISADVANTAGES OF REAL-TIME POINT-OF-CARE RT-PCR DEVICES 42.
TABLE 3 PCR TECHNOLOGIES MARKET: UNMET NEEDS 49.
TABLE 4 STRATEGIC FOCUS OF TIER-1/2/3 PLAYERS 50.
TABLE 5 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES 51.
TABLE 6 PCR TECHNOLOGIES MARKET: ROLE IN ECOSYSTEM 55.
TABLE 7 INDICATIVE PRICING OF PCR SYSTEMS, BY KEY PLAYER, 2025 56.
TABLE 8 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION,.
2023–2025 (USD) 59.
TABLE 9 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND) 60.
TABLE 10 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND) 61.
TABLE 11 PCR TECHNOLOGIES MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 62.
TABLE 12 US ADJUSTED RECIPROCAL TARIFF RATES 65.
TABLE 13 INNOVATIONS AND PATENT REGISTRATIONS, 2021–2026 69.
TABLE 14 KEY COMPANIES IMPLEMENTING AI/GEN AI IN PCR TECHNOLOGIES MARKET 72.
TABLE 15 KEY APPLICATIONS AND INDUSTRIAL OUTCOMES ENABLED BY PCR TECHNOLOGIES 74.
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 76.
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 77.
TABLE 18 PCR TECHNOLOGIES MARKET: UNMET NEED ANALYSIS 78.
TABLE 19 US: CLASSIFICATION OF PCR TECHNOLOGY-ASSOCIATED DIAGNOSTIC DEVICES 79.
TABLE 20 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 80.
TABLE 21 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 80.
TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 81.
TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 82.
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82.
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83.
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83.
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84.
TABLE 28 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84.
TABLE 29 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 86.
TABLE 30 PCR TECHNOLOGIES MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 87.
TABLE 31 PCR TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION,.
2024–2031 (USD MILLION) 88.
TABLE 32 PCR TECHNOLOGIES MARKET FOR SOFTWARE AND SERVICES, BY REGION,.
2024–2031 (USD MILLION) 89.
TABLE 33 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 91.
TABLE 34 REAL-TIME PCR MARKET, BY REGION, 2024–2031 (USD MILLION) 92.
TABLE 35 CONVENTIONAL PCR MARKET, BY REGION, 2024–2031 (USD MILLION) 93.
TABLE 36 DIGITAL PCR MARKET, BY REGION, 2024–2031 (USD MILLION) 94.
TABLE 37 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR 95.
TABLE 38 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2024–2031 (USD MILLION) 96.
TABLE 39 BENEFITS AND CONSIDERATIONS OF HOT-START PCR TECHNOLOGY 97.
TABLE 40 HOT-START PCR MARKET, BY REGION, 2024–2031 (USD MILLION) 97.
TABLE 41 MULTIPLEX PCR MARKET, BY REGION, 2024–2031 (USD MILLION) 98.
TABLE 42 OTHER PCR TECHNIQUES MARKET, BY REGION, 2024–2031 (USD MILLION) 99.
TABLE 43 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 101.
TABLE 44 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 102.
TABLE 45 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION,.
2024–2031 (USD MILLION) 103.
TABLE 46 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION,.
2024–2031 (USD MILLION) 104.
TABLE 47 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 105.
TABLE 48 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION,.
2024–2031 (USD MILLION) 106.
TABLE 49 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION,.
2024–2031 (USD MILLION) 107.
TABLE 50 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 108.
TABLE 51 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION,.
BY REGION, 2024–2031 (USD MILLION) 109.
TABLE 52 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION,.
2024–2031 (USD MILLION) 110.
TABLE 53 PCR TECHNOLOGIES MARKET, BY END USER, 2024–2031 (USD MILLION) 112.
TABLE 54 PCR TECHNOLOGIES MARKET FOR HOSPITAL LABORATORIES, BY REGION,.
2024–2031 (USD MILLION) 113.
TABLE 55 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 114.
TABLE 56 PCR TECHNOLOGIES MARKET FOR ACADEMIC AND GOVERNMENT ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 115.
TABLE 57 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2024–2031 (USD MILLION) 116.
TABLE 58 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION,.
2024–2031 (USD MILLION) 117.
TABLE 59 PCR TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 119.
TABLE 60 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 121.
TABLE 61 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 121.
TABLE 62 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 122.
TABLE 63 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 122.
TABLE 64 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER,.
2024–2031 (USD MILLION) 123.
TABLE 65 US: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 124.
TABLE 66 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 124.
TABLE 67 CANADA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 125.
TABLE 68 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 126.
TABLE 69 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 70 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 127.
TABLE 71 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 128.
TABLE 72 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 128.
TABLE 73 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER,.
2024–2031 (USD MILLION) 129.
TABLE 74 GERMANY: PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 130.
TABLE 75 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 130.
TABLE 76 FRANCE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 131.
TABLE 77 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 132.
TABLE 78 UK: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 133.
TABLE 79 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 133.
TABLE 80 ITALY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 134.
TABLE 81 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 134.
TABLE 82 SPAIN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 135.
TABLE 83 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 136.
TABLE 84 REST OF EUROPE : PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 137.
TABLE 85 REST OF EUROPE : PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 137.
TABLE 86 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 139.
TABLE 87 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 139.
TABLE 88 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 140.
TABLE 89 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 140.
TABLE 90 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY END USER,.
2024–2031 (USD MILLION) 141.
TABLE 91 CHINA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 142.
TABLE 92 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 142.
TABLE 93 JAPAN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 143.
TABLE 94 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 144.
TABLE 95 INDIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 145.
TABLE 96 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024–2031 (USD MILLION) 145.
TABLE 97 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 146.
TABLE 98 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 146.
TABLE 99 SOUTH KOREA : PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 147.
TABLE 100 SOUTH KOREA : PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 148.
TABLE 101 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 148.
TABLE 102 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 149.
TABLE 103 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 150.
TABLE 104 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 150.
TABLE 105 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 151.
TABLE 106 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 151.
TABLE 107 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER,.
2024–2031 (USD MILLION) 152.
TABLE 108 BRAZIL: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 153.
TABLE 109 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 153.
TABLE 110 MEXICO : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 154.
TABLE 111 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 154.
TABLE 112 REST OF LATIN AMERICA : PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 155.
TABLE 113 REST OF LATIN AMERICA : PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 155.
TABLE 114 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY REGION,.
2024–2031 (USD MILLION) 156.
TABLE 115 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 157.
TABLE 116 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 157.
TABLE 117 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,.
2024–2031 (USD MILLION) 158.
TABLE 118 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER,.
2024–2031 (USD MILLION) 158.
TABLE 119 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY PRODUCT,.
2024–2031 (USD MILLION) 159.
TABLE 120 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 160.
TABLE 121 REST OF THE MIDDLE EAST & AFRICA : PCR TECHNOLOGIES MARKET,.
BY PRODUCT, 2024–2031 (USD MILLION) 161.
TABLE 122 REST OF THE MIDDLE EAST & AFRICA : PCR TECHNOLOGIES MARKET,.
BY TECHNIQUE, 2024–2031 (USD MILLION) 161.
TABLE 123 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET 162.
TABLE 124 PCR TECHNOLOGIES MARKET: DEGREE OF COMPETITION 166.
TABLE 125 PCR TECHNOLOGIES MARKET: PRODUCT FOOTPRINT 171.
TABLE 126 PCR TECHNOLOGIES MARKET: APPLICATION FOOTPRINT 172.
TABLE 127 PCR TECHNOLOGIES MARKET: TECHNIQUE FOOTPRINT 173.
TABLE 128 PCR TECHNOLOGIES MARKET: END USER FOOTPRINT 174.
TABLE 129 PCR TECHNOLOGIES MARKET: REGION FOOTPRINT 175.
TABLE 130 PCR TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES PLAYERS 178.
TABLE 131 PCR TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 179.
TABLE 132 PCR TECHNOLOGIES MARKET: PRODUCT LAUNCHES AND APPROVALS,.
JANUARY 2022–SEPTEMBER 2026 181.
TABLE 133 PCR TECHNOLOGIES MARKET: DEALS, JANUARY 2022–SEPTEMBER 2026 182.
TABLE 134 PCR TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2022–SEPTEMBER 2026 183.
TABLE 135 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 184.
TABLE 136 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 185.
TABLE 137 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2026 187.
TABLE 138 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–SEPTEMBER 2026 188.
TABLE 139 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 190.
TABLE 140 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 191.
TABLE 141 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,.
JANUARY 2022–SEPTEMBER 2026 192.
TABLE 142 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–SEPTEMBER 2026 194.
TABLE 143 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 196.
TABLE 144 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 197.
TABLE 145 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–SEPTEMBER 2026 199.
TABLE 146 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS,.
JANUARY 2022–SEPTEMBER 2026 200.
TABLE 147 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 201.
TABLE 148 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 202.
TABLE 149 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES,.
JANUARY 2022–SEPTEMBER 2026 204.
TABLE 150 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–SEPTEMBER 2026 205.
TABLE 151 QIAGEN: COMPANY OVERVIEW 207.
TABLE 152 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 208.
TABLE 153 QIAGEN: PRODUCT LAUNCHES AND APPROVALS,.
JANUARY 2022–SEPTEMBER 2026 210.
TABLE 154 QIAGEN: DEALS, JANUARY 2022–SEPTEMBER 2026 211.
TABLE 155 QIAGEN: EXPANSIONS, JANUARY 2022–SEPTEMBER 2026 212.
TABLE 156 DANAHER CORPORATION: COMPANY OVERVIEW 214.
TABLE 157 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 215.
TABLE 158 DANAHER CORPORATION: PRODUCT APPROVALS,.
JANUARY 2022–SEPTEMBER 2026 217.
TABLE 159 DANAHER CORPORATION: DEALS, JANUARY 2022–SEPTEMBER 2026 217.
TABLE 160 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022–SEPTEMBER 2026 218.
TABLE 161 ABBOTT: COMPANY OVERVIEW 219.
TABLE 162 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED 220.
TABLE 163 ABBOTT: DEALS, JANUARY 2022–SEPTEMBER 2026 221.
TABLE 164 TAKARA BIO INC.: COMPANY OVERVIEW 222.
TABLE 165 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 223.
TABLE 166 TAKARA BIO INC.: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2026 224.
TABLE 167 TAKARA BIO INC.: DEALS, JANUARY 2021–DECEMBER 2024 225.
TABLE 168 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW 226.
TABLE 169 ANALYTIK JENA GMBH+CO. KG: PRODUCTS/SERVICES/SOLUTIONS OFFERED 226.
TABLE 170 ANALYTIK JENA GMBH+CO. KG: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2026 227.
TABLE 171 ANALYTIK JENA GMBH+CO. KG: DEALS, JANUARY 2022–SEPTEMBER 2026 228.
TABLE 172 EPPENDORF SE: COMPANY OVERVIEW 229.
TABLE 173 EPPENDORF SE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 230.
TABLE 174 EPPENDORF SE: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2026 231.
TABLE 175 EPPENDORF SE: DEALS, JANUARY 2022–SEPTEMBER 2026 231.
TABLE 176 MERCK KGAA: COMPANY OVERVIEW 232.
TABLE 177 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 233.
TABLE 178 MERCK KGAA: DEALS, JANUARY 2022–SEPTEMBER 2026 236.
TABLE 179 MERCK KGAA: EXPANSIONS, JANUARY 2022–SEPTEMBER 2026 236.
TABLE 180 BIONEER CORPORATION: COMPANY OVERVIEW 237.
TABLE 181 BIONEER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 238.
TABLE 182 BIONEER CORPORATION: OTHER DEVELOPMENTS,.
JANUARY 2022–SEPTEMBER 2026 239.
TABLE 183 REVVITY: COMPANY OVERVIEW 240.
TABLE 184 REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 241.
TABLE 185 REVVITY: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2026 242.
TABLE 186 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2026 242.
TABLE 187 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 243.
TABLE 188 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 244.
TABLE 189 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2026 245.
TABLE 190 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–SEPTEMBER 2026 246.
TABLE 191 BIOMÉRIEUX: COMPANY OVERVIEW 247.
TABLE 192 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED 248.
TABLE 193 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2026 249.
TABLE 194 STANDARD BIOTOOLS: COMPANY OVERVIEW 250.
TABLE 195 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 251.
TABLE 196 HOLOGIC, INC.: COMPANY OVERVIEW 253.
TABLE 197 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 254.
TABLE 198 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2026 255.
TABLE 199 LONZA: COMPANY OVERVIEW 256.
TABLE 200 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 257.
TABLE 201 ILLUMINA, INC.: COMPANY OVERVIEW 258.
TABLE 202 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 259.
TABLE 203 SANSURE BIOTECH INC.: COMPANY OVERVIEW 260.
TABLE 204 SANSURE BIOTECH INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 261.
TABLE 205 PROMEGA CORPORATION: COMPANY OVERVIEW 262.
TABLE 206 LIMINGBIO: COMPANY OVERVIEW 263.
TABLE 207 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW 264.
TABLE 208 DAAN GENE CO., LTD.: COMPANY OVERVIEW 265.
TABLE 209 BIOBASE GROUP: COMPANY OVERVIEW 266.
TABLE 210 NIPPON GENETICS EUROPE: COMPANY OVERVIEW 267.
TABLE 211 STILLA: COMPANY OVERVIEW 268.
TABLE 212 GENSCRIPT: COMPANY OVERVIEW 269.
TABLE 213 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 270.
TABLE 214 PCR TECHNOLOGIES MARKET: STUDY ASSUMPTIONS 283.
TABLE 215 PCR TECHNOLOGIES MARKET: RISK ASSESSMENT 284.